Rose J B, Watcha M F
Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, PA, USA.
Br J Anaesth. 1999 Jul;83(1):104-17. doi: 10.1093/bja/83.1.104.
The past decade has witnessed the introduction of several significant innovations to combat POV, particularly the introduction of serotonin antagonists and the use of combinations of drugs for analgesia and control of POV. Based on current knowledge, the anaesthetic plan for a patient with a previous history of severe PONV and undergoing a procedure known to be associated with a high incidence of this problem should include premedication with a benzodiazepine and/or clonidine and the preferential use of regional anaesthetic techniques. If general anaesthesia is essential, anaesthetists should consider the use of propofol for both induction and maintenance of anaesthesia, together with avoidance of nitrous oxide, opioids and neuromuscular antagonists. Pain control is extremely important, and a peripheral regional block should be used if possible. A combination of prophylactic antiemetics such as dexamethasone, a 5-HT3 antagonist and an antiemetic of a different class (e.g. perphenazine or dimenhydrinate) should be administered. Non-pharmacological measures such as acupressure and suggestion should also be considered, together with nursing measures to avoid sudden movement from one position to another during the postoperative period. A quiet environment, adequate i.v. fluids and not forcing the patient to drink before discharge all contribute to decreased emesis. It is possible that the advent of a new class of antiemetic agents, the NKI antagonists, may have major effects on the incidence of this complication. Drugs in this group differ from other currently available drugs in having the ability to effectively block the emetic response to many stimuli in experimental animals. Postoperative vomiting remains a significant problem, resulting in patient suffering and prolonged recovery from anaesthesia. Our aim should be to eliminate this complication in all children who require surgery. It should not be considered merely as the 'big, little problem'.
在过去十年中,为对抗术后恶心呕吐(POV)引入了多项重大创新措施,尤其是5-羟色胺拮抗剂的引入以及联合用药用于镇痛和控制术后恶心呕吐。根据目前的知识,对于有严重术后恶心呕吐既往史且即将接受已知与该问题高发生率相关手术的患者,麻醉方案应包括使用苯二氮䓬类药物和/或可乐定进行术前用药,并优先使用区域麻醉技术。如果必须进行全身麻醉,麻醉医生应考虑使用丙泊酚进行麻醉诱导和维持,同时避免使用氧化亚氮、阿片类药物和神经肌肉阻滞剂。疼痛控制极为重要,如有可能应使用外周区域阻滞。应给予预防性止吐药联合使用,如地塞米松、5-羟色胺3拮抗剂和另一类别的止吐药(如奋乃静或茶苯海明)。还应考虑非药物措施,如穴位按压和暗示,以及术后期间避免患者突然从一个体位移动到另一个体位的护理措施。安静的环境、充足的静脉输液以及在出院前不强迫患者饮水,所有这些都有助于减少呕吐。一类新型止吐药——神经激肽(NKI)拮抗剂的出现,可能会对该并发症的发生率产生重大影响。该组药物与目前其他可用药物的不同之处在于,它能够有效阻断实验动物对多种刺激的呕吐反应。术后呕吐仍然是一个重大问题,导致患者痛苦并延长麻醉恢复时间。我们的目标应该是在所有需要手术的儿童中消除这一并发症。它不应仅仅被视为一个“大的小问题”。